These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 15168738

  • 1. K65R, TAMs and tenofovir.
    Miller MD.
    AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
    [Abstract] [Full Text] [Related]

  • 2. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ, Chappey C, Parkin NT, Miller MD.
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [Abstract] [Full Text] [Related]

  • 3. HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.
    Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B.
    HIV Med; 2006 Jul; 7(5):294-8. PubMed ID: 16945074
    [Abstract] [Full Text] [Related]

  • 4. Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
    Wirden M, Marcelin AG, Simon A, Kirstetter M, Tubiana R, Valantin MA, Paris L, Bonmarchand M, Conan F, Kalkias L, Katlama C, Calvez V.
    J Med Virol; 2005 Jul; 76(3):297-301. PubMed ID: 15902696
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Jul; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V, Larder BA.
    Antivir Ther; 2001 Jul; 6 Suppl 3():25-44. PubMed ID: 11678471
    [Abstract] [Full Text] [Related]

  • 9. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
    Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW.
    AIDS; 2007 Jul 11; 21(11):1405-14. PubMed ID: 17589186
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.
    Antivir Ther; 2006 Jul 11; 11(2):233-43. PubMed ID: 16640104
    [Abstract] [Full Text] [Related]

  • 12. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
    Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C, Calvez V.
    J Med Virol; 2004 Jan 11; 72(1):162-5. PubMed ID: 14635026
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ.
    J Infect Dis; 2003 Oct 01; 188(7):992-1000. PubMed ID: 14513419
    [Abstract] [Full Text] [Related]

  • 17. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R, Lanier ER, Rouse EG, Oie KL, Pappa KA, Ross LL.
    Antivir Ther; 2008 Oct 01; 13(5):735-7. PubMed ID: 18771059
    [Abstract] [Full Text] [Related]

  • 18. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
    Kagan RM, Merigan TC, Winters MA, Heseltine PN.
    Antivir Ther; 2004 Oct 01; 9(5):827-8. PubMed ID: 15535422
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.
    J Med Virol; 2007 Feb 01; 79(2):105-10. PubMed ID: 17177308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.